Skip to main content
. 2015 Jun 10;6(26):22666–22679. doi: 10.18632/oncotarget.4433

Figure 7. Real-time cell-viability of A549 by using the xCELLigence system after sequential treatment with CDDP and Nutlin-3.

Figure 7

A. Normalized cell index over time after mono- and sequential combination therapy. B. Percentage of cell survival x hours after the start of treatment 2 (Nutlin-3).